22 results about "Drug/agent" patented technology

The invention relates to bacillus velezensis, a biocontrol inoculant prepared from the bacillus velezensis and application of the biocontrol inoculant, and belongs to the technical field of biological inoculants. The bacillus velezensis provided by the invention is bacillus velezensis and is named as JK1, the preservation unit is China General Microbiological Culture Collection Center, the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No.3, No.1 Yard, West Beichen Road, Chaoyang District, Beijing, the number of the preservation center is CGMCC No.31375, and the preservation time is July 19, 2024. The bacillus JK1 disclosed by the invention has relatively excellent bacteriostatic action on different pathogenic bacteria regardless of living bacteria, supernate or cell lysis solution. The bacillus JK1 is high in living ability and wide in application range of nutrient sources, temperature, humidity and pH value. The compound has no pathogenicity to fruits and vegetables, has good tolerance to broad-spectrum bactericides, and has a great application prospect.

The invention discloses a streptomycete N1 strain for inhibiting phytopathogen, a biocontrol inoculant and application of the biocontrol inoculant. The classification name of the Streptomyces sp. Is Streptomyces sp., the Streptomyces sp. Is preserved in the China Center for Type Culture Collection, and the preservation number of the Streptomyces sp. Is CCTCC NO: M 20242700. Experiments prove that the streptomyces N1 strain can significantly inhibit a variety of phytopathogens such as fusarium oxysporum, botryosphaeria dothidea, fusarium graminearum, acremonium nucleatum, botrytis cinerea, sclerotinia sclerotiorum and phytophthora nicotianae. A biological control fungicide prepared from the streptomyces N1 strain can effectively control plant soil-borne diseases, has the characteristics of high efficiency, environmental protection, low cost and easiness in preparation, is an optimal scheme for agricultural sustainable development, and has a good and wide market application prospect.

Provided herein are composition, systems, kits, and methods for preventing and / or treating, reversing, and / or inhibiting progression of, a neurodegenerative and / or neurological conditions and / or eye conditions (e.g., retinitis pigmentosa) by administering a plurality of nanoparticles to a subject via subcutaneous, intramuscular, or intraperitoneal injection such that the plurality of nanoparticles are taken up by lymphatic capillaries and are transported to neurological and / or eye tissue of the subject via the subject's lymphatic system, wherein the plurality of nanoparticles encapsulate, or are attached or absorbed to, at least one drug agent.

The utility model relates to the technical field of medicament mixing assistors, and discloses a double-component medicament opposite-extrusion mixing assistor which comprises a transverse plate, a transverse plate and a transverse plate, the two fixed seats are oppositely mounted on two sides of one end of the transverse plate; the extrusion roller is rotationally mounted between the two fixed seats through a rotating shaft; the clamping groove is formed in the outer wall of the extrusion roller in the axial direction of the extrusion roller; and the pressing mechanism is arranged in the clamping groove and used for pressing the bag tail in the clamping groove. According to the double-component medicament opposite-extrusion mixing assist device, the tail part of a medicament bag is fixed in the clamping groove, and when the extrusion roller rotates, the extrusion force generated when the bottom of the medicament bag penetrates through a gap between the extrusion roller and the transverse plate is utilized, so that the medicament bag can be uniformly extruded, time and labor are saved, and the mixing efficiency of the double-component medicament is improved.

The present invention is an implantable medical device comprising (i) a base coat layer having an inner and outer surface, the inner surface of the base coat layer contacting the implantable medical device; (ii) a top-coat layer of a hydrophilic polymer chemically crosslinked and covalently bonded to the outer surface of the base coat layer, the hydrophilic polymer comprising an anionic polyelectrolyte; and (iii) an amount of a hydrophilic cationic drug agent added to the top-coat layer sufficient to provide an effective dosage of the drug agent for delivery to a patient, whereby the hydrophilic cationic drug agent is initially adsorbed into the anionic polyelectrolyte of the top-coat layer and the hydrophilic cationic drug agent having a release rate after the medical device is implanted within a patient's body.

The present invention is an implantable medical device comprising (i) a base coat layer having an inner and outer surface, the inner surface of the base coat layer contacting the implantable medical device; (ii) a top-coat layer of a hydrophilic polymer chemically crosslinked and covalently bonded to the outer surface of the base coat layer, the hydrophilic polymer comprising an anionic polyelectrolyte; and (iii) an amount of a hydrophilic cationic drug agent added to the top-coat layer sufficient to provide an effective dosage of the drug agent for delivery to a patient, whereby the hydrophilic cationic drug agent is initially adsorbed into the anionic polyelectrolyte of the top-coat layer and the hydrophilic cationic drug agent having a release rate after the medical device is implanted within a patient's body.

The present invention relates to the field of microbial technology, and in particular to a strain of Paenibacillus polymyxa Se202205, a bacterial agent and an application. The Paenibacillus polymyxa Se202205 was deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration on September 15, 2023, with a deposit number of CGMCC No. 28465. The Paenibacillus polymyxa Se202205 strain provided by the present invention not only has a good antagonistic effect on a variety of plant pathogenic fungi, but also has the ability to efficiently convert sodium selenite to generate nano-selenium, and has good development and application potential in selenium-enriched microbial preparations of biocontrol agents.

The present disclosure describes a lipid-polymer hybrid nanoparticle and a method of synthesizing such a nanoparticle or a composition containing such a nanoparticle. These nanoparticles are made from a biodegradable polymer-based micellar core surrounded by a lipid-based shell, wherein a majority of the agent is present on the inner periphery of such nanoparticles due to physical adhesion to lipid molecules. Only a small amount of medicament is encapsulated in the micelle core. Thus, the lipid-based shell becomes the primary excipient part of the nanoparticle, and the core containing the biodegradable polymer becomes the secondary excipient part of the nanoparticle.

The invention relates to a Velez bacillus JSBV55 and a biocontrol agent and a preparation method and application thereof, and a method for preventing and treating garlic purple spot disease. The deposit number of the Velez bacillus strain JSBV55 is CGMCC NO.24637; the strain and the biocontrol agent containing the strain can effectively prevent and treat garlic purple spot disease. The invention has the advantages that, compared with chemical prevention and treatment, Velez bacillus JSBV55 and the biocontrol agent containing Velez bacillus JSBV55 can prevent and treat garlic purple spot disease, which belongs to biological prevention and treatment, has low toxicity, is degradable, and has no pollution to the environment. While effectively preventing and treating garlic purple spot disease, the green and sustainable development of the garlic industry is realized.

The invention relates to the technical field of microorganisms, in particular to an antagonistic strain D86 and a biocontrol inoculant and application thereof, the antagonistic strain D86 is bacillus subtilis D86 and is preserved in the China Center for Type Culture Collection on November 11, 2024, the preservation number is CCTCC NO: M 20242514, and the antagonistic strain D86 is classified and named as Bacillus subtilis D86. The bacillus subtilis is separated from saline-alkali soil, has a remarkable antagonistic effect on walnut tree rot pathogenic bacteria cyst aureocladium and cryptosphere, and has a good prevention and treatment effect on walnut branch rot under an in-vitro condition.

A method of preparing a hybrid virus hydrogel, is provided, the method comprising contacting a virus-like particle (VLP) or derivative thereof comprising an alkyne moiety with a swelled hydrogel comprising an azide group. Hydrogel compositions as well as methods of using them are further provided herein. Further provided herein are compositions as well as methods of use for hybrid virus hydrogels comprising additional therapeutic drug agents.

The present application discloses a crank-connecting rod-type breathing-synchronized inhalation apparatus, comprising a housing, wherein a suction mouthpiece is arranged at the bottom of the housing, and a medicine bottle is movably arranged inside the housing; an elastic assembly is arranged at the top of the medicine bottle and can push the medicine bottle to move, so that the bottle body compresses a nozzle, thereby causing the suction mouthpiece to spray medicine; a mounting assembly is fixedly arranged on the inner wall of the housing; two ends of a connecting rod assembly are hinged to the elastic assembly and the mounting assembly, respectively, and the connecting rod assembly has a first state and a second state; a toggle assembly can be deformed by a suction force generated when a person inhales by means of the suction mouthpiece, so that the connecting rod assembly is switched from the first state to the second state, thereby removing the restraint placed on the elastic assembly, so that the elastic assembly pushes the medicine bottle, thereby causing the nozzle to spray a drug agent; thus, the inhalation of air is synchronized with the inhalation of the drug agent, achieving high sensitivity and good stability; a counting assembly is arranged in an upper cover, and the counting assembly performs a count after the connecting rod assembly is switched from the second state to the first state, which allows a patient to conveniently track the number of remaining doses in the medicine bottle, so that the medicine bottle can be replaced in time.

Pharmaceutical compositions of the invention include substituted riluzole pro drugs useful for the treatment of amyotrophic lateral sclerosis (ALS) and related disorders through the release of riluzole, especially to avoid patient to patient variability in first pass, hepatic metabolism promoted by Cyp 1Λ2. Pro-drugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release rihizole in the plasma via either an enzymatic or general biophysical release process. The invention further includes pro-drugs of riluzole useful for the treatment of disease states that can be treated with riluzole through the release of rihizole from a pro-drug agent.

The present application relates to the technical field of biotechnology, and aims to provide a Bacteroides uniformis with activity against porcine epidemic diarrhea virus and application thereof. The strain is preserved in China Center for Type Culture Collection, and the preservation name is Bacteroides uniformis ZJNB01, the Latin name is Bacteroides uniformis, and the preservation number is CCTCC NO: M 20241757. The porcine-derived Bacteroides uniformis has significant probiotic properties; due to rapid growth, it has strong resistance to porcine epidemic diarrhea virus. The Bacteroides uniformis and / or its metabolites can be used as a drug active center to produce a drug agent, and have a wide application scenario in the prevention and treatment of porcine epidemic diarrhea virus.

This disclosure provides an iontophoresis drug delivery device. The iontophoresis drug delivery device includes: a power source for generating pulsed direct current required to penetrate a drug agent into a drug delivery area of ​​a biological organism, wherein the power source generates a positive pulsed direct current in a first time period and a reverse pulsed direct current in a second time period; a dielectric layer for contacting the drug delivery area, wherein the dielectric layer includes or has an active agent attached thereto, the active agent being used to penetrate into the drug delivery area via the pulsed direct current; and at least two electrodes for receiving the pulsed direct current output from the power source to provide the received pulsed direct current to the dielectric layer. The iontophoresis drug delivery device provided by this disclosure not only improves transdermal efficiency but also minimizes skin irritation or damage.

The present invention relates to the field of biological control technology, and in particular to a strain of Pantoea pineapple FY611 and its application and biocontrol agent. The Pantoea pineapple FY611 provided by the present invention is an indispensable and important bacterial resource, which can be used to create a biological pesticide preparation and has great application value in the green prevention and control of the recently outbreak of rice bacterial blight. The Pantoea pineapple FY611 was deposited in the China General Microbiological Culture Collection Center on November 6, 2023, with a deposit number of CGMCC No. 28885.

A method of preparing a hybrid virus hydrogel, is provided, the method comprising contacting a virus-like particle (VLP) or derivative thereof comprising an alkyne moiety with a swelled hydrogel comprising an azide group. Hydrogel compositions as well as methods of using them are further provided herein. Further provided herein are compositions as well as methods of use for hybrid virus hydrogels comprising additional therapeutic drug agents.

Provided herein are compositions, systems, articles of manufacture, and methods of treating a subject with: i) an APE2 inhibitor, and ii) a drug agent that causes increased expression of APE2 in said subject. In certain embodiments, the drug agent is Cisplatin or similar drug.

The invention provides a bacillus subtilis, a microbial agent and an application for preventing and treating konjac soft rot, and belongs to the technical field of biocontrol microbial agent development. The bacillus subtilis GY1 of the invention has the function of preventing and treating konjac soft rot, and the deposit number is CGMCC No.31159. The invention also develops a biocontrol microbial agent that can be directly applied based on the characteristics of the bacillus subtilis GY1, and performs microbial agent root irrigation treatment on konjac during the growth period of konjac, which can effectively prevent and treat konjac soft rot, increase konjac yield, improve soil quality in konjac planting areas, and alleviate konjac continuous cropping obstacles.

The invention discloses a strain of Bacillus Velez QN2320, a biocontrol agent and an application thereof. The Bacillus Velez QN2320 is deposited in the China Center for Type Culture Collection, and its deposit number is CCTCC NO: M 20241601. The invention also discloses a biocontrol agent, whose active ingredients include the bacterial body, bacterial liquid, fermentation filtrate or active extract of the Bacillus Velez QN2320. The Bacillus Velez has excellent antagonistic effects on various plant disease pathogens such as Diplodia pine, Fusarium graminearum and Cordyceps sinensis, has a broad-spectrum antibacterial property, and has high antibacterial activity. It can be used as a biocontrol agent for the prevention and treatment of various plant diseases such as pine trunk rot, wheat stem base rot, apple rot, and apple ring rot, and has good market application prospects.

The invention discloses an entomopathogen preparation for preventing and controlling sweet potato weevil beetles as well as a preparation method and application of the entomopathogen preparation, and belongs to the technical field of agriculture. The entomopathogenic preparation for preventing and treating the sweet potato small weevils disclosed by the invention comprises an entomopathogenic nematode corpse compound agent and a sweet potato root protective agent, wherein the entomopathogenic nematode corpse compound agent comprises an entomopathogenic nematode corpse agent, an ipomoea batatas artificial feed, a polyphenol oxidase inhibitor and trehalose (alpha, alpha) dry powder in a mass ratio of (1-3): (6-8): (0.25-0.35): (0.6-0.8); every 1L of the sweet potato root protective agent contains 0.03-0.05 g of the biocontrol microbial agent, 3-5g of the sweet potato small weevil repelling agent, 90-110ml of the binder and the balance of water. The invention further discloses a preparation method of the entomopathogen preparation and application of the entomopathogen preparation in prevention and treatment of the sweet potato weevil. The entomopathogenic preparation disclosed by the invention plays a role in preventing and treating the sweet potato weevil jointly through multiple actions, and has a good preventing and treating effect on imagoes and larvae of the sweet potato weevil.

The present invention relates to the technical field of biological pesticides, and in particular to a Bacillus firmus for preventing and treating cotinus canker and its biocontrol agent and application. Bacillus firmus HG‑13c has been deposited in the General Microbiological Center of the China Microbiological Culture Collection Committee on July 15, 2022, with a deposit address of No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and a deposit number of CGMCC No. 25308; the strain and its biocontrol agent can be used to inhibit the growth of Botrytis cinerea and / or prevent and treat cotinus canker. The biocontrol agent containing Bacillus firmus HG‑13c provided by the present invention can achieve a 14-day protection effect of 61.48% and a 21-day protection effect of 65.02% in field experiments; in particular, when used in combination with Bacillus megaterium BMJBN02, the 14-day protection effect can reach 88.69%, and the 21-day protection effect can reach 89.12%.